STOCK TITAN

C4 Therapeutics Inc - CCCC STOCK NEWS

Welcome to our dedicated news page for C4 Therapeutics (Ticker: CCCC), a resource for investors and traders seeking the latest updates and insights on C4 Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect C4 Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of C4 Therapeutics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.69%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.86%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags
clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.4%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.14%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.06%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.95%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.01%
Tags
management clinical trial
C4 Therapeutics Inc

Nasdaq:CCCC

CCCC Rankings

CCCC Stock Data

560.47M
52.51M
14.22%
68.09%
7.71%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Watertown

About CCCC

c4 therapeutics is an early stage drug discovery company whose mission is to harness targeted protein degradation to develop therapeutics for a broad range of diseases. the centerpiece of our approach is the degronimid® platform, which enables highly selective small molecule binders to target disease causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system.